OTC · BPTH
Healthcare · Biotechnology
$0.00
Up+$0.00 (+400.00%)
Updated Oct 7, 2026, 2:23 AM
SID Score
3.4/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · BPTH
1M range · 3 trading sessions · Daily adjusted prices
Prices through Sep 15, 2026
BPTH closed at $0.00 after 3 trading sessions, down 66.67% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $0.0001 | $0.0001 | $0.0001 | $0.0001 | 6.4K |
| Sep 11, 2026 | $0.0001 | $0.0001 | $0.0001 | $0.0001 | 3.48K |
| Sep 10, 2026 | $0.0003 | $0.0003 | $0.0003 | $0.0003 | 290 |
The latest Smart Investors Daily articles mentioning BPTH.
Company
Market Activity
Research & News
BPTH research
Company profile and research snapshot.
BIO-PATH HOLDINGS INC
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 8, 2024 | Roth MKM | Buy | — |
| Apr 18, 2024 | Roth MKM | Buy | — |
| Mar 27, 2024 | Roth MKM | Buy | — |
| May 19, 2022 | HC Wainwright & Co. | Buy | — |
| Mar 11, 2021 | Roth Capital | Buy | — |
No generated briefing is available yet.
GlobeNewswire Inc. · Jun 3, 2025
Bio-Path Holdings, a biotechnology company, announced progress in its clinical trials for cancer and obesity treatments using its DNAbilize® platform. The company highlighted positive results and upcoming milestones for its drug candidates, including prexigebersen, BP1001-A, and BP1002.
GlobeNewswire Inc. · Jan 10, 2025
Bio-Path Holdings, a biotechnology company, provides a clinical development and operational update for 2025. The company is advancing multiple programs, including a Phase 2 trial for acute myeloid leukemia, Phase 1/1b trials for solid tumors and relapsed/refractory acute myeloid leukemia, and preclinical development for obesity in Type 2 Diabetes patients.
GlobeNewswire Inc. · Dec 11, 2024
Bio-Path Holdings is developing BP1001-A, an antisense drug targeting the Grb2 protein, as a potential treatment for obesity and type 2 diabetes. The company is conducting preclinical studies to determine the effectiveness of BP1001-A in affecting insulin signaling and its potential as a therapeutic for obese patients with type 2 diabetes.
GlobeNewswire Inc. · Oct 9, 2024
Bio-Path Holdings, a biotechnology company, announced a $4.0 million private placement financing. The company plans to use the proceeds for working capital and general corporate purposes.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BPTH.
